Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Purpose Our objectives were (1) to compare the disposition and in vivo release of paclitaxel between a tocopherol-based Cremophor-free formulation (Tocosol Paclitaxel) and Cremophor EL-formulated paclitaxel (Taxol) in human subjects, and (2) to develop a mechanistic model for unbound and total paclitaxel pharmacokinetics. Methods A total of 35 patients (average +/- SD age: 59 +/-13 years) with advanced non-hematological malignancies were studied in a randomized two-way crossover trial. Patients received 175 mg/m(2) paclitaxel as 15 min (Tocosol Paclitaxel) or 3 h (Taxol) intravenous infusion in each study period. Paclitaxel concentrations were determined by LC-MS/MS in plasma ultrafiltrate and whole blood. NONMEM VI was used for population pharmacokinetics. Results A linear disposition model with three compartments for unbound paclitaxel and a one-compartment model for Cremophor were applied. Total clearance of unbound paclitaxel was 845 L/h (variability: 25% CV). The prolonged release with Tocosol Paclitaxel was explained by the limited solubility of unbound paclitaxel of 405 ng/mL (estimated) in plasma. The 15 min Tocosol Paclitaxel infusion yielded a mean time to 90% cumulative input of 1.14 +/- 0.16 h. Tocosol Paclitaxel was estimated to release 9.8% of the dose directly into the deep peripheral compartment. The model accounted for the presence of drug-containing nanodroplets in blood. Conclusions Population pharmacokinetic analysis indicated linear disposition and a pote…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It should be pointed out that both Wan et al. [188] and Bulitta et al. [248] models relied on stability of the micelles and did not account for a situation where formulation could influence the unbound drug concentration, like in the case of equilibrium micelle binding.”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [248]
In the citing paper
“This has also been studied earlier by Bulitta et al., who came to develop similar models to represent the regular micelle and emulsions systems [248].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [248]
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Simplified calculation of body surface area
(1987) · New England Journal of Medicine · doi:10.1056/nejm198710223171717 · Cited by 3,238 · cited 1×
“The BSA was calculated by the Mosteller formula [24] and used to describe body size and to scale all clearance and volume terms linearly by BSA.”
MethodHypersensitivity reactions from taxol.
Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker, J. R., Van Echo, D. A., Von Hoff, D. D., & Leyland-Jones, B. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1263 · Cited by 1,174
Ibrahim, N. K., Desai, N. P., Legha, S. S., Soon‐Shiong, P., Theriault, R. L., Rivera, E., Esmaeli, B., Ring, S. E., Bedikian, A. Y., Hortobágyi, G. N., et al. (2002) · PubMed · Cited by 705
Clinical toxicities encountered with paclitaxel (Taxol).
Rowinsky, E. K., Eisenhauer, E. A., Chaudhry, V., Sg, A., & Rc, D. (1993) · PubMed · Cited by 692
Gianni, L., Kearns, C. M., Giani, A., Capri, G., Viganó, L., Lacatelli, A., Bonadonna, G., & Egorin, M. J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.180 · Cited by 553
(1999) · PubMed · Cited by 337
Self-citationSparreboom, A., van Tellingen, O., Nooijen, W. J., & Beijnen, J. H. (1996) · PubMed · Cited by 313
Role of Formulation Vehicles in Taxane Pharmacology
van Zuylen, L., Verweij, J., & Sparreboom, A. (2001) · Investigational New Drugs · doi:10.1023/a:1010618632738 · Cited by 293
Wiernik, P. H., Schwartz, E. L., Einzig, A., Strauman, J. J., Lipton, R. B., & Dutcher, J. P. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.8.1232 · Cited by 275
Ligand-Targeted Liposomes for Cancer Treatment
Sapra, P., Tyagi, P., & Allen, T. (2005) · Current Drug Delivery · doi:10.2174/156720105774370159 · Cited by 246
Pharmacology and Toxicology of Cremophor EL Diluent
Dorr, R. T. (1994) · Annals of Pharmacotherapy · doi:10.1177/10600280940280s503 · Cited by 227
Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients
Tellingen, O. V., Huizing, M. T., Panday, V. R. N., Schellens, J. H. M., Nooijen, W. J., & Beijnen, J. H. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690696 · Cited by 211
Henningsson, A., Marsh, S., Loos, W. J., Karlsson, M. O., Garsa, A., Mross, K., Mielke, S., Viganò, L., Locatelli, A., Verweij, J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1152 · Cited by 188
A phase I trial of taxol given by a 6-hour intravenous infusion.
Brown, T., Havlin, K., Weiss, G., Cagnola, J., Koeller, J., Kuhn, J., Rizzo, J., Craig, J., Phillips, J., & Von Hoff, D. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.7.1261 · Cited by 180
Pharmaceutical and Physical Properties of Paclitaxel (Taxol †) Complexes with Cyclodextrins ‡
Sharma, U. S., Balasubramanian, S. V., & Straubinger, R. M. (1995) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600841015 · Cited by 168
Mechanism-Based Pharmacokinetic Model for Paclitaxel
Henningsson, A., Karlsson, M. O., Viganò, L., Gianni, L., Verweij, J., & Sparreboom, A. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.20.4065 · Cited by 156
Tocol emulsions for drug solubilization and parenteral delivery
Constantinides, P. P., Tustian, A. K., & Kessler, D. R. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.12.005 · Cited by 153
Self-citationTaxol metabolism and disposition in cancer patients.
Walle, T., Walle, U. K., Kumar, G. N., & Bhalla, K. N. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06589-4 · Cited by 147
Paclitaxel pharmacokinetics and pharmacodynamics.
Kearns, C. M., Gianni, L., & Egorin, M. J. (1995) · PubMed · Cited by 140
Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors.
Sonnichsen, D. S., Hurwitz, C. A., Pratt, C. B., Shuster, J. J., & Relling, M. V. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.3.532 · Cited by 136
Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles
van Zuylen, L., Karlsson, M. O., Verweij, J., Brouwer, E., de Bruijn, P., Nooter, K., Stoter, G., & Sparreboom, A. (2001) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800000215 · Cited by 133
Formulation Development and Antitumor Activity of a Filter-Sterilizable Emulsion of Paclitaxel
Constantinides, P. P., Lambert, K. J., Tustian, A. K., Schneider, B., Lalji, S., Ma, W., Wentzel, B., Kessler, D. R., Worah, D. M., & Quay, S. C. (2000) · Pharmaceutical Research · doi:10.1023/a:1007565230130 · Cited by 130
Self-citationTissue distribution, metabolism and excretion of paclitaxel in mice
Sparreboom, A., van Tellingen, O., Nooijen, W. J., & Beijnen, J. H. (1996) · Anti-Cancer Drugs · doi:10.1097/00001813-199601000-00009 · Cited by 128
Joerger, M., Huitema, A. D. R., van den Bongard, D. H. J. G., Schellens, J. H. M., & Beijnen, J. H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2069 · Cited by 120
van Tellingen, O., Beijnen, J. H., Verweij, J., Scherrenburg, E. J., Nooijen, W. J., & Sparreboom, A. (1999) · PubMed · Cited by 113
Potential neurotoxicity of the solvent vehicle for cyclosporine.
Windebank, A. J., Blexrud, M. D., & de Groen, P. C. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38962-7 · Cited by 105
Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein.
Kumar, G. N., Walle, U. K., Bhalla, K. N., & Walle, T. (1993) · PubMed · Cited by 98
Measurement of Fraction Unbound Paclitaxel in Human Plasma
Brouwer, E., Verweij, J., De Bruijn, P., Loos, W. J., Pillay, M., Buijs, D., & Sparreboom, A. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12040-8 · Cited by 98
Enhancement of water-solubility and bioactivity of paclitaxel using modified cyclodextrins
Hamada, H., Ishihara, K., Masuoka, N., Mikuni, K., & Nakajima, N. (2006) · Journal of Bioscience and Bioengineering · doi:10.1263/jbb.102.369 · Cited by 97
Hepatic metabolism and biliary excretion of Taxol in rats and humans.
Monsarrat, B., Alvinerie, P., Wright, M., Dubois, J., Guéritte, F., Guénard, D., Donehower, R. C., & Rowinsky, E. K. (1993) · PubMed · Cited by 86
Comparative Pharmacokinetics of Unbound Paclitaxel During 1- and 3-Hour Infusions
Gelderblom, H. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.2.574 · Cited by 82
Self-citationSparreboom, A., Verweij, J., van der Burg, M. E. L., Loos, W. J., Brouwer, E., Viganò, L., Locatelli, A., de Vos, A. I., Nooter, K., Stoter, G., et al. (1998) · PubMed · Cited by 82
Henningsson, A., Sparreboom, A., Sandström, M., Freijs, A., Larsson, R. L., Bergh, J. C. S., Nygren, P., & Karlsson, M. O. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00126-6 · Cited by 81
Pharmacokinetic Models for the Saturable Distribution of Paclitaxel
Karlsson, M. O., Molnar, V., Freijs, A., Nygren, P., Bergh, J., & Larsson, R. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15049-0 · Cited by 80
PROPERTIES OF CREMOPHOR EL MICELLES PROBED BY FLUORESCENCE
Kessel, D. H. (1992) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.1992.tb02187.x · Cited by 62
Quantitation of Cremophor EL in Human Plasma Samples Using a Colorimetric Dye-Binding Microassay
Sparreboom, A., Loos, W. J., Verweij, J., de Vos, A. I., van der Burg, M. E. L., Stoter, G., & Nooter, K. (1998) · Analytical Biochemistry · doi:10.1006/abio.1997.2467 · Cited by 53
Preparation and Characterization of Taxane-Containing Liposomes
Straubinger, R. M., & Balasubramanian, S. V. (2005) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(05)91005-7 · Cited by 51
Brat, D. J., Aj, W., & Brimijoin, S. (1992) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11107-5 · Cited by 47
Disposition of [G-3H]paclitaxel and Cremophor EL in a Patient with Severely Impaired Renal Function
Gelderblom, H. A. J., Verweij, J., Brouwer, E., Pillay, M., de Bruijn, P., Nooter, K., Stoter, G., & Sparreboom, A. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14932-x · Cited by 28
Self-citationExtensive and saturable accumulation of paclitaxel by the human platelet
Wild, M. D., Walle, U. K., & Walle, T. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685730 · Cited by 24
Mould, D. R., Fleming, G. F., Darcy, K. M., & Spriggs, D. R. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02718.x · Cited by 22
A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling
van den Bongard, H. J. G. D., Mathôt, R. A. A., van Tellingen, O., Schellens, J. H. M., & Beijnen, J. H. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-002-0459-x · Cited by 17
Population pharmacokinetics of low-dose paclitaxel in patients with brain tumors
Hempel, G., Rübe, C., Mosler, C., Wienstroer, M., Wagner‐Bohn, A., Schuck, A., Willich, N. A., & Boos, J. (2003) · Anti-Cancer Drugs · doi:10.1097/00001813-200307000-00005 · Cited by 11
Dhanikula, A. B., Panchagnula, R., Singh, I., Kaur, K., Kaul, C. L., & Sekhon, J. S. (2001) · Methods and Findings in Experimental and Clinical Pharmacology · doi:10.1358/mf.2001.23.2.627937 · Cited by 2
Research works printed but not linked: 1
- Beal SL, Sheiner LB, Boeckmann AJ (2006) NONMEM Users Guides (1989–2006). Icon Development Solutions, Ellicott City
Cited by
Cragg, G. M., & Pezzuto, J. M. (2016) · Medical Principles and Practice · doi:10.1159/000443404 · Cited by 798
Hwang, D., Ramsey, J. D., & Kabanov, A. V. (2020) · Advanced drug delivery reviews · doi:10.1016/j.addr.2020.09.009 · Cited by 699
Paclitaxel Nano-Delivery Systems: A Comprehensive Review
Ma, P. (2013) · Journal of Nanomedicine & Nanotechnology · doi:10.4172/2157-7439.1000164 · Cited by 559
Nanocarrier for Poorly Water-Soluble Anticancer Drugs—Barriers of Translation and Solutions
Narvekar, M., Xue, H. Y., Eoh, J. Y., & Wong, H. L. (2014) · AAPS PharmSciTech · doi:10.1208/s12249-014-0107-x · Cited by 257
(2019) · Profiles of Drug Substances, Excipients and Related Methodology · doi:10.1016/bs.podrm.2018.11.001 · Cited by 159
Metadata
- Authors
- Bulitta, J. B., Zhao, P., Arnold, R. D., Kessler, D. R., Daifuku, R., Pratt, J., Luciano, G., Hanauske, A.-R., Gelderblom, H., Awada, A., & Jusko, W. J.
- Affiliations
- University at Buffalo, State University of New York (US)
- University of Georgia (US)
- Asklepios Klinik St. Georg (DE)
- Leiden University Medical Center (NL)
- Institut Jules Bordet (BE)
- Corresponding author
- Jusko, William J.
- ORCID
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2008-09-13
- Volume
- 63
- Issue
- 6
- Pages
- 1049-1063
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W2089920524
- Cited by
- 47
- References
- 45
- Citations by year
- 2025: 1 · 2024: 3 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 1 · 2019: 4 · 2018: 3 · 2017: 5 · 2016: 3 · 2015: 4 · 2014: 2 · 2013: 6 · 2012: 5
- FWCI
- 0.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Chemotherapy and Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- paclitaxel, Cremophor EL, population pharmacokinetic model, drug release kinetics, bioavailability, infusion duration, non-hematological malignancies
- MeSH terms
- Adult, Antineoplastic Agents, Phytogenic, Chemistry, Pharmaceutical, Chromatography, Liquid, Female, Humans, Leukocyte Count, Male, Middle Aged, Models, Biological, Monte Carlo Method, Neoplasms, Structure-Activity Relationship, Tissue Distribution, Linear Models, Drug Delivery Systems, Paclitaxel, Cross-Over Studies, Tandem Mass Spectrometry, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.